Cell therapy weekly: Phase II/III gene therapy trial for mucopolysaccharidosis type IIIA reports patient death

Written by RegMedNet

This week: a Phase II/III gene therapy trial for mucopolysaccharidosis type IIIA has reported that a patient has passed away, Bayer acquires Asklepios BioPharmaceutical to broaden their cell and gene therapy portfolio, and TreeFrog Therapeutics has been awarded the Galien MedStartup prize for their QC-Stem International Consortium on iPSC quality. The news highlights: Phase II/III gene therapy trial for mucopolysaccharidosis type IIIA reports patient death Bayer acquires Asklepios BioPharmaceutical to broaden cell and gene therapy portfolio TreeFrog Therapeutics awarded Galien MedStartup for their consortium on iPSC quality   Phase II/III gene therapy trial for mucopolysaccharidosis type IIIA reports patient death...

To view this content, please register now for access

It's completely free